Press Releases

Press Releases

Date Title and Summary Additional Formats
Aug 01, 2019 Catalyst Pharmaceuticals Announces Its Support of Spinal Muscular Atrophy Awareness Month
CORAL GABLES, Fla. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Jul 31, 2019 Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019
CORAL GABLES, Fla. , July 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Jun 12, 2019 Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration
Complaint Cites Multiple Violations of Food, Drug, and Cosmetic Act CORAL GABLES, Fla. , June 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration ( FDA ) and several related parties
Jun 04, 2019 Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
CORAL GABLES, Fla. , June 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
May 30, 2019 Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan
CORAL GABLES, Fla. , May 30, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
May 13, 2019 Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update
-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse -Company to Host Quarterly Conference Call at 8:30 am ET Today CORAL GABLES, Fla.
May 06, 2019 Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 13th, 2019
CORAL GABLES, Fla. , May 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Mar 18, 2019 Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
CORAL GABLES, Fla. , March 18, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Mar 11, 2019 Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019
CORAL GABLES, Fla. , March 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Feb 28, 2019 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019
CORAL GABLES, Fla. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

Displaying 11 - 20 of 24